EU: Court of Justice aide takes first step to clarify patent litigation limits
An aide to the European Court of Justice has suggested that there are some instances in which patent litigation over standard-essential patents is legitimate and justified, say reports.
EU lawmakers are in the midst of debating rules for patent litigation as critics demand crackdowns on patent trolls and anticompetitive lawsuits. But Advocate General Melchoir Wathelet of the EU Court of Justice offered an advisory opinion stating that a company that owns technology is not by default wrong to bring legal action to attempt to bar other companies from using that technology.
He argues that such patent litigation is legitimate when a patent owner, without abusing market dominance, seeks damages for patent infringement before a licensing agreement was made.
Wathelet’s remarks were part of a request for guidance by a German court as technology giants Huawei and ZTE battle out patent infringement litigation regarding 4G wireless technology. According to reports, the case at the Court of Justice is the first to handle the scope of SEPs and the rights of their owners.
While the European Commission has implied through previous rulings that SEP owners are wrong to seek an injunction in certain circumstances, Wathelet suggests that it is only wrong to seek an injunction against a company that is “willing and able to enter into” a licensing agreement.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Court to Hear Case on Trump’s Firing of FTC Democrats
May 20, 2025 by
CPI
UK Government Suffers Third Successive Defeat on Data (Use and Access) Bill
May 20, 2025 by
CPI
Sex Toy Retailer Says Google Breaches EU Digital Market Rules
May 20, 2025 by
CPI
Latham & Watkins Expands Brussels Antitrust Team
May 20, 2025 by
CPI
Brazil’s Antitrust Watchdog Expected to Approve Pet Retail Merger Without Conditions
May 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas